Comparison of effects of tocilizumab and tumor necrosis factor α inhibitors on rheumatoid arthritis disease activity during 16-week treatment. (A) C-reactive protein (CRP). (B) Vascular endothelial growth factor (VEGF). (C) Disease Activity Score in 28 joints (DAS28), tender joint count (TJC), Visual Analogue Scale (VAS) score and rheumatoid factor (RF). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values are means and SEM. *P < 0.01, vs. baseline by paired t-test. #P < 0.01 and $P < 0.05 by paired t-test for comparison of changes from baseline between the two groups at 16 weeks.